

# Prof. Mustafa ÖZGÜROĞLU

## Personal Information

**Birthyear:** 1964

**Place of birth:** K.K.T.C

**Office Phone:** [+90 212 414 3017](tel:+902124143017)

**Fax Phone:** [+90 212 414 3017](tel:+902124143017)

**Email:** [mozgur@iuc.edu.tr](mailto:mozgur@iuc.edu.tr)

**Other Email:** [ozguroglu@gmail.com](mailto:ozguroglu@gmail.com)

**Web:** <http://avesis.istanbulc.edu.tr/1662/>

**Address:** Cerrahpaşa- Fatih istanbul

## Education Information

1993 - 1996	Post Doctorate of Medicine, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji, Turkey
1988 - 1993	Expertise In Medicine, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları , Turkey

## Foreign Languages

French, B1 Intermediate English, C1 Advanced

## Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

## Academic Titles / Tasks

1988 - Continues Professor, Istanbul University, Dahili Bilimler

## Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.**  
Garassino M. C. , Paz-Ares L., Hui R., Faivre-Finn C., Spira A., Planchard D., Özgüroğlu M., Daniel D., Vicente D., Murakami S., et al.  
Future oncology (London, England), 2021 (Journal Indexed in SCI Expanded)
- II. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.**  
Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al.  
Lancet (London, England), vol.397, pp.592-604, 2021 (Journal Indexed in SCI Expanded)
- III. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.**  
Park K., Özgüroğlu M., Vansteenkiste J., Spigel D., Yang J. C. , Bajars M., Ruisi M., Manitz J., Barlesi F.  
Lung cancer (Amsterdam, Netherlands), vol.154, pp.92-98, 2021 (Journal Indexed in SCI Expanded)

- IV. **Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.**  
 Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F. , Spigel D. R. , Garassino M. C. , Reck M., Senan S., et al.  
 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 (Journal Indexed in SCI Expanded)
- V. **The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer.**  
 Celik E., Samanci N. S. , Karadag M., Demirci N. S. , Demirelli F. H. , Ozguroglu M.  
 Medical oncology (Northwood, London, England), vol.38, pp.11, 2021 (Journal Indexed in SCI Expanded)
- VI. **Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.**  
 Lu S., Casarini I., Kato T., Cobo M., Özgüroğlu M., Hodge R., van der Gronde T., Saggese M., Ramalingam S. S.  
 Clinical lung cancer, 2021 (Journal Indexed in SCI Expanded)
- VII. **Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).**  
 Faivre-Finn C., Spigel D., Senan S., Langer C., Perez B., Özgüroğlu M., Daniel D., Villegas A., Vicente D., Hui R., et al.  
 Lung cancer (Amsterdam, Netherlands), vol.151, pp.30-38, 2020 (Journal Indexed in SCI Expanded)
- VIII. **Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.**  
 Moehler M., Dvorkin M., Boku N., Özgüroğlu M., Ryu M., Muntean A., Lonardi S., Nechaeva M., Bragagnoli A., Coşkun H., et al.  
 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 (Journal Indexed in SCI Expanded)
- IX. **Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110**  
 Herbst R. S. , De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., et al.  
 SWISS MEDICAL WEEKLY, 2020 (Journal Indexed in SCI)
- X. **Final overall survival analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration resistant prostate cancer and homologous recombination repair (HRR) gene alterations.**  
 Sandhu S., de Bono J., Mateo J., Fizazi K., Fred S., Shore N., Chi K., Sartor O., Agarwal N., Olmos D., et al.  
 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.16, pp.41, 2020 (Journal Indexed in SCI)
- XI. **Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.**  
 Herbst R., Giaccone G., de M., Reinmuth N., Vergnenegre A., Barrios C., Morise M., Felip E., Andric Z., Geater S., et al.  
 The New England journal of medicine, vol.383, pp.1328-1339, 2020 (Journal Indexed in SCI Expanded)
- XII. **First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes**  
 Schulz C., Chen Y., Paz-Ares L. G. , Dvorkin M., Trukhin D., Reinmuth N., Garassino M. C. , Statsenko G., Voitko O., Hochmair M. J. , et al.  
 ONCOLOGY RESEARCH AND TREATMENT, vol.43, pp.144-145, 2020 (Journal Indexed in SCI)
- XIII. **Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study**  
 Grohe C., Paz-Ares L. G. , Dvorkin M., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , Ozguroglu M., Ji J. H. , et al.  
 ONCOLOGY RESEARCH AND TREATMENT, vol.43, pp.149, 2020 (Journal Indexed in SCI)
- XIV. **Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.**  
 Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K., Sartor O., Agarwal N., Olmos D., et al.  
 The New England journal of medicine, 2020 (Journal Indexed in SCI Expanded)
- XV. **PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.**

Huddart R., Siefker-Radtke A., Balar A., Bilen M., Powles T., Bamias A., Castellano D., Khalil M., Van D., Koshkin V., et al.

Future oncology (London, England), 2020 (Journal Indexed in SCI Expanded)

- XVI. **Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.**  
Goldman J., Garassino M., Chen Y., Özgüroğlu M., Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J., Hochmair M., et al.  
Lung cancer (Amsterdam, Netherlands), vol.149, pp.46-52, 2020 (Journal Indexed in SCI Expanded)
- XVII. **Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer**  
Sengul S., Cikman D., Oruc K., Bedir S., Çelik E., Degerli E., Derin S., Demirelli F. H. , Özgüroğlu M.  
TUMORI J, 2020 (Journal Indexed in SCI)
- XVIII. **Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial**  
Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C. , Ozguroglu M., Daniel D., Villegas A., Vicente D., Hui R., et al.  
ANNALS OF ONCOLOGY, vol.31, no.6, pp.798-806, 2020 (Journal Indexed in SCI)
- XIX. **Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).**  
Naidoo J., Vansteenkiste J. F. , Faivre-Finn C., Ozguroglu M., Murakami S., Hui R., Quantin X., Broadhurst H., Newton M., Dennis P. A. , et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XX. **Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial**  
Galsky M. D. , Arranz Arija J. A. , Bamias A., Davis I. D. , De Santis M., Kikuchi E., Garcia-del-Muro X., De Giorgi U., Mencinger M., Izumi K., et al.  
LANCET, vol.395, no.10236, pp.1547-1557, 2020 (Journal Indexed in SCI)
- XXI. **The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.**  
Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Vivaldi C., Olesinski T., Caglevic C., Chung H. C. , et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXII. **First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.**  
Chen Y., Paz-Ares L. G. , Dvorkin M., Trukhin D., Reinmuth N., Chiara Garassino M., Statsenko G., Voitko O., Hochmair M., Ozguroglu M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXIII. **Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.**  
Disel U., Kose F., Bilici A., Ozguroglu M., Saglam S., Seker M., Aksoy S., Tek I., Eralp Y., Mandel N. M. , et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXIV. **Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.**  
Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., Chung H. C. , et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXV. **The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.**  
Shitara K., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandal M., Ryu M., Vivaldi C., Olesinski T., Chung H. C. , Muro K., et al.

- JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXVI. **Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.**  
Paz-Ares L. G. , Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M., Ozguroglu M., Ji J. H. , et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXVII. **Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.**  
Matsubara N., Chi K., Özgüroğlu M., Rodriguez-Antolin A., Feyerabend S., Fein L., Alekseev B., Suler G., Protheroe A., Li S., et al.  
European urology, vol.77, pp.494-500, 2020 (Journal Indexed in SCI)
- XXVIII. **IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC**  
Herbst R., De Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C., Morise M., Font E., Andric Z., Geater S., et al.  
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol.8, 2020 (Journal Indexed in SCI)
- XXIX. **First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC**  
Faehling M., Planchard D., Cho B. C. , Gray J. E. , Paz-Ares L. G. , Ozguroglu M., Villegas A. E. , Daniels D. B. , Vicente D., Murakami S., et al.  
ONCOLOGY RESEARCH AND TREATMENT, vol.43, pp.120, 2020 (Journal Indexed in SCI)
- XXX. **Central, Prospective Detection of Homologous Recombination Repair (HRR) Gene Alteration in Tumor Tissue From > 4000 Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Screened for The Profound Study**  
Stenzl A., Hussain M., Fizazi K., Saad F., Shore N., Sandhu S., Mehra N., Kolinsky M., Roubaud G., Ozguroglu M., et al.  
ONCOLOGY RESEARCH AND TREATMENT, vol.43, pp.81, 2020 (Journal Indexed in SCI)
- XXXI. **Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab +/- Tremelimumab plus Chemotherapy in ES-SCLC**  
Reinmuth N., Paz-Ares L., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , Ozguroglu M., Li J. H. , Voitko O., et al.  
ONCOLOGY RESEARCH AND TREATMENT, vol.43, pp.115, 2020 (Journal Indexed in SCI)
- XXXII. **Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC**  
Gray J. E. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , Cho B. C. , et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.15, no.2, pp.288-293, 2020 (Journal Indexed in SCI)
- XXXIII. **Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study**  
Hui R., ÖZGÜROĞLU M., Villegas A., Daniel D., Vicente D., Murakami S., Yokoi T., Chiappori A., Lee K. H. , de Wit M., et al.  
LANCET ONCOLOGY, vol.20, no.12, pp.1670-1680, 2019 (Journal Indexed in SCI)
- XXXIV. **Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.**  
PAZ-ARES L., DVORKIN M., CHEN Y., REINMUTH N., HOTTA K., TRUKHIN D., STATSENKO G., HOCHMAIR M., Özgüroğlu M., Ji J., et al.  
Lancet (London, England), vol.394, pp.1929-1939, 2019 (Journal Indexed in SCI)
- XXXV. **Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.**  
AGARWAL N., MCQUARRIE K., BJARTELL A., CHOWDHURY S., PEREIRA D. S. G. A. , CHUNG B., Özgüroğlu M., Juárez

- S., MERSEBURGER A., UEMURA H., et al.  
The Lancet. Oncology, vol.20, pp.1518-1530, 2019 (Journal Indexed in SCI)
- XXXVI. **2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC)**  
Barlesi F., Ozguroglu M., Vansteenkiste J., Spigel D., Yang J., Ishii H., Garassino M., de Marinis F., Szczesna A., Polychronis A., et al.  
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol.7, 2019 (Journal Indexed in SCI)
- XXXVII. **Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study**  
Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M. J., Ozguroglu M., Ji J. H., Voitko O., et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (Journal Indexed in SCI)
- XXXVIII. **Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.**  
CHI K., AGARWAL N., BJARTELL A., CHUNG B., PEREIRA D. S. G. A., GIVEN R., Juárez S., MERSEBURGER A., Özgüroğlu M., UEMURA H., et al.  
The New England journal of medicine, vol.381, pp.13-24, 2019 (Journal Indexed in SCI)
- XXXIX. **Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.**  
LEVY B., PAZ-ARES L., BENNOUNA J., FELIP E., ABREU D., ISLA D., BARLESI F., MOLINIER O., MADELAINE J., AUDIGIER-VALETTE C., et al.  
Clinical lung cancer, vol.20, 2019 (Journal Indexed in SCI)
- XL. **Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.**  
FIZAZI K., TRAN N., FEIN L., MATSUBARA N., RODRIGUEZ-ANTOLIN A., ALEKSEEV B., Özgüroğlu M., YE D., FEYERABEND S., PROTHEROE A., et al.  
The Lancet. Oncology, vol.20, pp.686-700, 2019 (Journal Indexed in SCI)
- XLI. **KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.**  
KATO K., SHAH M., ENZINGER P., BENNOUNA J., SHEN L., ADENIS A., SUN J., CHO B., Özgüroğlu M., KOJIMA T., et al.  
Future oncology (London, England), vol.15, pp.1057-1066, 2019 (Journal Indexed in SCI)
- XLII. **TITAN, a phase 3 study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)**  
Merseburger A. S., Chowdhury S., Agarwal N., Bjartell A., Chung B. H., Pereira de Santana Gomes A. J., Given R. W., Soto A. J., Ozguroglu M., Uemura H., et al.  
ONCOLOGY RESEARCH AND TREATMENT, vol.42, pp.286, 2019 (Journal Indexed in SCI)
- XLIII. **Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.**  
ANTONIA S., VILLEGAS A., DANIEL D., VICENTE D., MURAKAMI S., HUI R., KURATA T., CHIAPPORI A., LEE K., de W., et al.  
The New England journal of medicine, vol.379, pp.2342-2350, 2018 (Journal Indexed in SCI)
- XLIV. **Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study**  
Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., de Marinis F., Ozguroglu M., Szczesna A., Polychronis A., Uslu R., et al.  
LANCET ONCOLOGY, vol.19, no.11, pp.1468-1479, 2018 (Journal Indexed in SCI)
- XLV. **PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT**  
Vansteenkiste J., Naidoo J., Faivre-Finn C., Ozguroglu M., Villegas A., Daniel D., Murakami S., Hui R., Lee K., Cho B. C., et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- XLVI. **Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-**

- Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.**  
 JERUSALEM G., de B., HURVITZ S., YARDLEY D., KOVALENKO E., EJLERTSEN B., BLAU S., Özgüroglu M., LANDHERR L., EWERTZ M., et al.  
 JAMA oncology, vol.4, pp.1367-1374, 2018 (Journal Indexed in SCI)
- XLVII. **Effect of Induction Chemotherapy in the PACIFIC Study**  
 Spigel D., Vansteenkiste J., Reck M., Wakelee H., Ozguroglu M., Daniel D., Villegas A., Vicente D., Hui R., Murakami S., et al.  
 JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- XLVIII. **Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial**  
 Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., De Marinis F., Ozguroglu M., Szczesna A., Polychronis A., Uslu R., et al.  
 JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- XLIX. **Outcomes of Patients < 70 or >= 70 Years of Age in PACIFIC**  
 Socinski M., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Gray J., Park K., Vincent M., et al.  
 JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- L. **Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC**  
 Antonia S., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , De Wit M., et al.  
 JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- LI. **Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%**  
 Spira A., Planchard D., Cho B. C. , Ozguroglu M., Daniel D., Villegas A., Vicente D., Hui R., Murakami S., Paz-Ares L., et al.  
 JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- LII. **Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents**  
 ANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J. , LAINEZ N., GONZALEZ I., CASTELLANO D. E. , Ozguroglu M., GARCIA CARBONERO I., FLECHON A., et al.  
 CLINICAL GENITOURINARY CANCER, vol.16, no.4, 2018 (Journal Indexed in SCI)
- LIII. **Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial**  
 SHITARA K., Ozguroglu M., BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., FORNARO L., OLESINSKI T., CAGLEVIC C., CHUNG H. C. , et al.  
 LANCET, vol.392, no.10142, pp.123-133, 2018 (Journal Indexed in SCI)
- LIV. **Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial**  
 Royce M., BACHELOT T., VILLANUEVA C., Ozguroglu M., AZEVEDO S. J. , CRUZ F. M. , DEBLED M., Hegg R., TOYAMA T., FALKSON C., et al.  
 JAMA ONCOLOGY, vol.4, no.7, pp.977-984, 2018 (Journal Indexed in SCI)
- LV. **Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.**  
 Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., Chung H. C. , et al.  
 JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- LVI. **Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung**  
 Levy B. P. , Paz-Ares L. G. , Bennouna J., Felip E., Abreu D. R. , Isla D., Barlesi F., Molinier O., Madelaine J., Audigier-Valette C., et al.  
 JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- LVII. **Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast**

**cancer (ABC): BOLERO-6, an open-label phase 2 study**

Jerusalem G. H. M. , Kovalenko E., Yardley D. A. , De Boer R. H. , Hurvitz S. A. , Ejlertsen B., Blau S., Ozguroglu M., Landherr L., Ewertz M., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)

- LVIII. **Subsequent treatment after abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.**  
Chi K. N. , Namphuon Tran N. T. , Feyerabend S., Matsubara N., Ozguroglu M., Fein L. E.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- LIX. **Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.**  
Fizazi K., Feyerabend S., Matsubara N., Ozguroglu M., Fein L. E. , Antolin A. R. , Alekseev B. Y. , Sulur G., Protheroe A., De Porre P., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- LX. **Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes**  
Hui R., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., Ryden A., Zhang Y., Dennis P., Antonia S.  
JOURNAL OF THORACIC ONCOLOGY, vol.13, no.4, 2018 (Journal Indexed in SCI)
- LXI. **Durvalumab in Stage III Non-Small-Cell Lung Cancer REPLY**  
Antonia S. J. , Ozguroglu M.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.378, no.9, pp.869-870, 2018 (Journal Indexed in SCI)
- LXII. **Durvalumab in Stage III Non-Small-Cell Lung Cancer.**  
Antonia S., Özgüroğlu M.  
The New England journal of medicine, vol.378, pp.869-870, 2018 (Journal Indexed in SCI)
- LXIII. **Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial**  
Martin M., Holmes F. A. , Ejlertsen B., Delalogue S., Moy B., Iwata H., von Minckwitz G., Chia S. K. L. , Mansi J., Barrios C. H. , et al.  
The Lancet Oncology, vol.18, no.12, pp.1688-1700, 2017 (Journal Indexed in SCI)
- LXIV. **Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC**  
Hui R., Ozguroglu M., Daniel D., Baz D., Murakami S., Yokoi T., Chiappori A., Lee K. H. , De Wit M., Cho B. C. , et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.12, no.11, 2017 (Journal Indexed in SCI)
- LXV. **Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer**  
Antonia S. J. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K. H. , de Wit M., et al.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.377, no.20, pp.1919-1929, 2017 (Journal Indexed in SCI)
- LXVI. **LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)**  
Feyerabend S., Tran N., Fein L., Matsubara N., Rodriguez Antolin A., Alekseev B., Ozguroglu M., Ye D., Protheroe A., De Porre P., et al.  
ONCOLOGY RESEARCH AND TREATMENT, vol.40, pp.113, 2017 (Journal Indexed in SCI)
- LXVII. **Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer**  
Fizazi K., Namphuon Tran N. T. , Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B. Y. , Ozguroglu M., Ye D., Feyerabend S., Protheroe A., et al.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.377, no.4, pp.352-360, 2017 (Journal Indexed in SCI)
- LXVIII. **LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.**  
Fizazi K., Namphuon Tran N. T. , Enrique Fein L., Matsubara N., Rodriguez Antolin A., Alekseev B. Y. , Ozguroglu M.,

Ye D., Feyerabend S., Protheroe A., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.35, no.18, 2017 (Journal Indexed in SCI)

- LXXIX. **Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study**  
Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., Caty A., Dujardin C., Auclin E., Thibaut C., et al.  
CLINICAL GENITOURINARY CANCER, vol.15, no.3, 2017 (Journal Indexed in SCI)
- LXX. **COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY**  
Altundag K., Basaran G., Oksuzoglu B., Oven B., Ozguroglu M., Aydin D., Hacibedel B., Helvacioglu K., Tuna E., Tatar M.  
VALUE IN HEALTH, vol.19, no.3, 2016 (Journal Indexed in SCI)
- LXXI. **Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?**  
Ozturk M. A., DANE F., Karagoz S., Tural D., Selcukbiricik F., Demirelli F., Buyukunal E., Ozguroglu M., Turna H., Erdamar S., et al.  
Hepato-Gastroenterology, vol.62, no.137, pp.59-64, 2015 (Journal Indexed in SCI Expanded)
- LXXII. **Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer**  
Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al.  
EUROPEAN JOURNAL OF CANCER, vol.50, no.9, pp.1602-1609, 2014 (Journal Indexed in SCI)
- LXXIII. **Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial**  
Andre F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., Masuda N., Wilks S., Arena F., Isaacs C., et al.  
LANCET ONCOLOGY, vol.15, no.6, pp.580-591, 2014 (Journal Indexed in SCI)
- LXXIV. **Receptor expression discrepancy between primary and metastatic breast cancer lesions**  
Ozen D. S. K., Öztürk M. S., Aydin O., Turna Z. H., Ilvan Ş., Ozguroglu M.  
Oncology Research and Treatment, vol.37, no.11, pp.622-626, 2014 (Journal Indexed in SCI Expanded)
- LXXV. **Quality-of-life in Turkish cancer patients: The impact of sociodemographic characteristics, medical history, and management Türk kanser hastaları{dotless}nda sosyodemografik karakteristiklerin, ti{dotless}bbi öykünün ve tedavilerin yaşam kalitesi üzerine etkisi**  
Toptas T., Yildiz I., Yildiz M., Varol U., Bayoglu I. V., Ozguroglu M.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.24, no.1, pp.23-29, 2014 (Journal Indexed in SCI Expanded)
- LXXVI. **BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine**  
Isaacs C., Ozguroglu M., Jerusalem G., Xu B., Lang I., O'Regan R., White M., Fasolo A., Litton J., Toi M., et al.  
CANCER RESEARCH, vol.73, 2013 (Journal Indexed in SCI)
- LXXVII. **Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series**  
Saygin C., Uzunaslari D., Ozguroglu M., Senocak M., Tuzuner N.  
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.88, no.2, pp.253-271, 2013 (Journal Indexed in SCI)
- LXXVIII. **Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial**  
Jerusalem G., Andre F., Chen D., Robinson D., Ozguroglu M., Lang I., White M., Toi M., Taran T., Gianni L.  
EUROPEAN JOURNAL OF CANCER, vol.49, 2013 (Journal Indexed in SCI)
- LXXIX. **Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial**  
Bahl A., Oudard S., Tombal B., Ozguroglu M., Hansen S., Kocak I., Gravis G., Devin J., Shen L., de Bono J. S., et al.  
ANNALS OF ONCOLOGY, vol.24, no.9, pp.2402-2408, 2013 (Journal Indexed in SCI)
- LXXX. **Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience**  
Selcukbiricik F., Buyukunal E., Tural D., Ozguroglu M., Demirelli F., Serdengeci S.  
WORLD JOURNAL OF GASTROENTEROLOGY, vol.19, no.14, pp.2154-2161, 2013 (Journal Indexed in SCI)



- LXXXI. **Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer**  
Tural D., Ozturk M., Selcukbiricik F., Yildiz O., Elicin O., Turna H., Guney S., Ozguroglu M.  
JOURNAL OF BUON, vol.18, no.2, pp.385-390, 2013 (Journal Indexed in SCI)
- LXXXII. **Patterns of complementary and alternative medicine use among turkish cancer patients**  
Yildiz I., Ozguroglu M., TOPTAŞ T., Turna H., Sen F., Yildiz M.  
Journal of Palliative Medicine, vol.16, no.4, pp.383-390, 2013 (Journal Indexed in SCI Expanded)
- LXXXIII. **The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer**  
Selcukbiricik F., Erdamar S., Ozkurt C. U. , Mandel N. M. , Demirelli F. H. , Ozguroglu M., Tural D., Buyukunal E., Serdengeci S.  
JOURNAL OF BUON, vol.18, no.1, pp.116-123, 2013 (Journal Indexed in SCI)
- LXXXIV. **Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey**  
SELÇUKBİRİCİK F., Tural D., Bilici A., Uzel E. K. , Ozguroglu M., Demirelli F., Buyukunal E., Serdengeci S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.1, pp.553-556, 2013 (Journal Indexed in SCI)
- LXXXV. **Primary osteosarcoma of the heart: Experience of an unusual case**  
Özen D. S. K. , Öztürk M. A. , Selcukbiricik F., Esatoglu S. N. , Turna Z. H. , Beyaz P., Dervisoglu S., Özgüroglu M.  
Case Reports in Oncology, vol.6, no.1, pp.224-228, 2013 (Journal Indexed in SCI Expanded)
- LXXXVI. **Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial**  
Ramlau R., Gorbunova V., Ciuleanu T. E. , Novello S., Ozguroglu M., GÖKSEL T., Baldotto C., Bennouna J., Shepherd F. A. , Le-Guenec S., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.30, no.29, pp.3640-3647, 2012 (Journal Indexed in SCI)
- LXXXVII. **Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain**  
Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.  
ONKOLOGIE, vol.35, no.5, pp.254-258, 2012 (Journal Indexed in SCI)
- LXXXVIII. **Prognostic factors for survival in the phase III TROPIC trial.**  
Sartor A. O. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Kocak I., Gravis G., Bodrogi I., MacKenzie M. J. , Orlandi F. J. , et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.30, no.5, 2012 (Journal Indexed in SCI)
- LXXXIX. **Synchronous detection of hairy cell leukemia and HIV-negative Kaposi's sarcoma of the lymph node: A diagnostic challenge and a rare coincidence**  
Aydin S. O. , Eskazan A. E. , Aki H., Ozguroglu M., Baslar Z., Soysal T.  
Case Reports in Oncology, vol.4, no.3, pp.439-444, 2011 (Journal Indexed in SCI Expanded)
- XC. **AFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)**  
Novello S., Ramlau R., Gorbunova V. A. , Ciuleanu T. E. , Ozguroglu M., GÖKSEL T., Baldotto C., Bennouna J., Shepherd F. A. , Scagliotti G.  
JOURNAL OF THORACIC ONCOLOGY, vol.6, no.6, 2011 (Journal Indexed in SCI)
- XCI. **Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.**  
Ozguroglu M., Oudard S., Sartor A. O. , Hansen S., Machiels J. H. , Shen L., De Bono J. S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XCII. **Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.**  
Sartor A. O. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., De Bono J. S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XCIII. **A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and**

**survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).**

De Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., Sartor A. O.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)

- XCIV. **Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study**  
Ozguroglu M., Oudard S., Sartor A. O. , Hansen S., Machiels J. H. , Shen L., De Bono J. S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.7, 2011 (Journal Indexed in SCI)
- XCIV. **CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT**  
Tombal B., Oudard S., Ozguroglu M., Hansen S., Kocak I., Gravis G., Sartor A. O. , Shen L., de Bono J. S.  
EUROPEAN UROLOGY SUPPLEMENTS, vol.10, no.2, pp.335-336, 2011 (Journal Indexed in SCI)
- XCVI. **Gastroenteropancreatic Neuroendocrine tumors: 10-Year experience in a single center**  
Yildiz O., Ozguroglu M., Yanmaz T., Turna H., Serdengeçti S., Dogusoy G.  
Medical Oncology, vol.27, no.4, pp.1050-1056, 2010 (Journal Indexed in SCI Expanded)
- XCVII. **Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: Report of first case**  
Bilici A., Ozguroglu M., Tuzuner N., Goksel S., Turna H.  
Archives of Gynecology and Obstetrics, vol.282, no.5, pp.587-590, 2010 (Journal Indexed in SCI Expanded)
- XCVIII. **Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial**  
de Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., Gravis G., Bodrogi I., Mackenzie M. J. , Shen L., et al.  
LANCET, vol.376, no.9747, pp.1147-1154, 2010 (Journal Indexed in SCI)
- XCIX. **Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)**  
De Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., Matthews P., Sartor A. O.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- C. **Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain**  
Dizdar O., Altundag M. K. , Ozkok S., Ozsaran Z., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- CI. **How does (18)f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?**  
Selcukbiricik F., Ozguroglu M., Ozturk M. A. , Ozgur N., Turna H., Tural D., Hallac M., Demirkiran F., Arvas M., Mandel N. M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- CII. **Surgery for isolated liver metastasis of ovarian cancer**  
Pekmezci S., Saribeyoglu K., Aytac E., Arvas M., Demirkiran F., Ozguroglu M.  
Asian Journal of Surgery, vol.33, no.2, pp.83-88, 2010 (Journal Indexed in SCI Expanded)
- CIII. **The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpaşa experience Mide karsinomlarında postoperatif kemoradyoterapi tedavi sonuçları: Cerrahpaşa deneyimi**  
Çolpan Öksüz D., Eren M. F. , Şenel Beşe N., Büyükuşal E., Özgüroğlu M., Molinas Mandel N., Turna H., Demirelli F., Serdengeçti S., Atkovar G., et al.  
Turk Onkoloji Dergisi, vol.25, no.1, pp.1-10, 2010 (Journal Indexed in SCI Expanded)
- CIV. **Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. "**  
TURNA Z. H. , ÖZGÜROĞLU M., BOLAYIRLI İ. M. , ORHANOĞLU T., BALCI H.

- CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, pp.454-457, 2009 (Journal Indexed in SCI Expanded)
- CV. **Is there any effect of tumor burden on hemostatic parameters in cancer patients? a case-control study of hemostatic abnormalities and anticardiolipin antibodies in solid tumors**  
Turna H., Ozguroglu M., Bolayirli M., Orhanoglu T., Balci H.  
Clinical and Applied Thrombosis/Hemostasis, vol.15, no.4, pp.454-457, 2009 (Journal Indexed in SCI Expanded)
- CVI. **Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case-Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors**  
TURNA Z. H. , ÖZGÜROĞLU M., BOLAYIRLI İ. M. , ORHANOĞLU T., BALCI H.  
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, no.4, pp.454-457, 2009 (Journal Indexed in SCI)
- CVII. **Metastasis from breast carcinoma to endometrial polyp**  
Aydin O., Bagci P., Akyildiz E. U. , Ozguroglu M., Ilvan Ş.  
European Journal of Gynaecological Oncology, vol.29, no.6, pp.666-668, 2008 (Journal Indexed in SCI Expanded)
- CVIII. **Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: A comparative study**  
Yilmaz M. H. , Ozguroglu M., Mert D., Turna H., Demir G., Adaletli I., Ulus S., Halac M., Kanberoglu K.  
Medical Oncology, vol.25, no.3, pp.257-263, 2008 (Journal Indexed in SCI Expanded)
- CIX. **Determining predominating histologic component in malignant mixed müllerian tumors: Is it worth it?**  
Ozguroglu M., Bilici A., Ilvan Ş., Turna H., Atalay B., Mandel N., Sahinler I.  
International Journal of Gynecological Cancer, vol.18, no.4, pp.809-812, 2008 (Journal Indexed in SCI Expanded)
- CX. **A case-control study of non-alcoholic fatty liver disease in breast cancer**  
Bilici A., Ozguroglu M., Mihmanlı I., Turna H., Adaletli I.  
Medical Oncology, vol.24, no.4, pp.367-371, 2007 (Journal Indexed in SCI Expanded)
- CXI. **Neuroblastoma in adults, presentation of 2 cases**  
Demir H., Aydin O., Durak H., Dervisoglu S., Ozguroglu M., Sahinler I.  
VIRCHOWS ARCHIV, vol.451, no.2, pp.577, 2007 (Journal Indexed in SCI)
- CXII. **Thymoma with chronic diarrhea: Report of two cases and review of the literature**  
Yildiz O., Ozguroglu M., TURNA H., YANMAZ T., Kaynak K., Akman C., CETİN S. E. , Oz B., ÇELİK A.  
Medical Oncology, vol.24, no.1, pp.119-123, 2007 (Journal Indexed in SCI Expanded)
- CXIII. **Paraneoplastic pemphigus associated with fludarabine use**  
Yıldız O., Özgüroğlu M., Yanmaz M. R. , Turna H., Kursunoglu S. G. , Antonov M., Serdaroglu S., Demirkesen C., Büyükkınal E.  
Medical Oncology, vol.24, no.1, pp.115-118, 2007 (Journal Indexed in SCI Expanded)
- CXIV. **The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy**  
Yilmaz M. H. , Esen G., Ayarcan Y., Aydogan F., Ozguroglu M., Demir G., Bese N., Mandel N. M.  
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol.13, no.1, pp.13-18, 2007 (Journal Indexed in SCI)
- CXV. **C-reactive protein as an acute phase protein in cancer patients**  
Bolayirli M., Turna H., ORHANOĞLU T., Ozaras R., İLHAN M., Ozguroglu M.  
Medical Oncology, vol.24, no.3, pp.338-344, 2007 (Journal Indexed in SCI Expanded)
- CXVI. **Megestrol acetate induced hypoadrenalism with cushingoid phenotype in endometrial cancer [1]**  
Ozguroglu M., Yildiz O., Turna H., Kadioglu P.  
Gynecologic Oncology, vol.101, no.1, pp.183, 2006 (Journal Indexed in SCI Expanded)
- CXVII. **Devastating effects of chemotherapy: Deafness and acute renal failure in a patient with epithelial ovarian cancer**  
Ozguroglu M., Sari O., Turna H.  
International Journal of Gynecological Cancer, vol.16, pp.394-396, 2006 (Journal Indexed in SCI Expanded)
- CXVIII. **Small cell carcinoma of the bladder: A case report and review of the literature**  
Tunc B., Ozguroglu M., Demirkesen O., Alan C., Durak H., Dinçbas F. O. , Kural A. R.  
International Urology and Nephrology, vol.38, no.1, pp.15-19, 2006 (Journal Indexed in SCI Expanded)
- CXIX. **Adult paratesticular myxofibrosarcoma: report of a rare entity and review of the literature.**  
OZKAN B., ÖZGÜROĞLU M., Ozkara H., DURAK H., TALAT Z.

International urology and nephrology, vol.38, pp.5-7, 2006 (Journal Indexed in SCI)

- CXX. **Toxicity and survival results of a phase II study investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma**  
Bese N., Buyukunal E., Ozguroglu M., Demir G., Yildirim A., Mandel N. K. , Demirelli F. H. , Serdengecti S., Ober A.  
STRAHLENTHERAPIE UND ONKOLOGIE, vol.181, no.10, pp.652-659, 2005 (Journal Indexed in SCI)
- CXXI. **Acute phase proteins in malignancy: role of CRP in the discrimination of infectious complications in cancer patients**  
Ozguroglu M., Bolayirli M., Orhanoglu T., Yildiz O., Turna H., Serdengecti S.  
EJC SUPPLEMENTS, vol.3, no.2, pp.70, 2005 (Journal Indexed in SCI)
- CXXII. **Idiopathic thrombocytopenia associated with dysgerminoma in a patient with androgen insensitivity syndrome**  
Yildiz O., Ozguroglu M.  
GYNECOLOGIC ONCOLOGY, vol.99, no.1, pp.248, 2005 (Journal Indexed in SCI)
- CXXIII. **Secretory carcinoma of the breast. Case report and review of the literature**  
Ozguroglu M., Tascilar K., Ilvan S., Soybir G., Celik V.  
Oncology, vol.68, pp.263-268, 2005 (Journal Indexed in SCI Expanded)
- CXXIV. **Delayed onset bleomycin-induced pneumonitis**  
Uzel I., Ozguroglu M., Uzel B., Kaynak K., Demirhan O., Akman C., Oz F., Yaman M.  
UROLOGY, vol.66, no.1, 2005 (Journal Indexed in SCI)
- CXXV. **Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: An experimental study**  
Yüceyar S., ERTÜRK Ş. M. , Temiz M., Doğusoy G., Gümüştas K., Özgüroğlu M., Cengiz A., Kafadar Y.  
Techniques in Coloproctology, vol.9, no.3, pp.201-205, 2005 (Journal Indexed in SCI Expanded)
- CXXVI. **Does the incidence of anal canal cancers differ in Moslem societies?**  
Yumuk P., Abacioglu U., Demir G., Cabuk D., Dane F., Gumus M., Ozguroglu M., Ekenel M., Basaran G., Turhal N.  
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol.20, no.1, pp.76, 2005 (Journal Indexed in SCI)
- CXXVII. **Rituximab-induced tumor progression: Does it really happen?**  
Ozguroglu M., Turna H.  
Medical Oncology, vol.21, no.2, pp.205-206, 2004 (Journal Indexed in SCI Expanded)
- CXXVIII. **Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma**  
Ozguroglu M., Bilici A., Turna H., Serdengecti S.  
Medical Oncology, vol.21, no.1, pp.67-72, 2004 (Journal Indexed in SCI Expanded)
- CXXIX. **Do we really benefit from checking tumor markers in detecting recurrence in gastrointestinal cancer?**  
Ozguroglu M., Turna H.  
Journal of B.U.ON., vol.9, no.2, pp.179-182, 2004 (Journal Indexed in SCI Expanded)
- CXXX. **Acute leukemia in a patient with ocular melanoma - Is it induced by Intraocular Brachytherapy or only a bad fate?**  
Ozguroglu M., Bese N., Karacam S., Pazarli H.  
MEDICAL ONCOLOGY, vol.21, no.4, pp.373-374, 2004 (Journal Indexed in SCI)
- CXXXI. **Should mammographic screening be done in primary ovarian cancer? A case control study in Turkish women**  
Ozguroglu M., Avci B., Turna H., Esen G., Arun B., Celik V., Serdengecti S.  
Medical Oncology, vol.21, no.2, pp.139-143, 2004 (Journal Indexed in SCI Expanded)
- CXXXII. **Mismanagement of cancer pain: Attitudes of physicians and perception of pain and its treatment by the cancer patients**  
Serdengecti S., Ozguroglu M., Toptas T., Velet M., Yanmaz T., Buyukunal E.  
ANNALS OF ONCOLOGY, vol.15, pp.211-212, 2004 (Journal Indexed in SCI)
- CXXXIII. **Multiple primary tumors in cancer patients in a Turkish population**  
Ozguroglu M., Donmez H., Turna H., Mandel N.  
ANNALS OF ONCOLOGY, vol.15, pp.149, 2004 (Journal Indexed in SCI)

- CXXXIV. **Intrathoracic extravasation of antineoplastic agents - Case report and systematic review**  
Bozkurt A., Uzel B., Akman C., Ozguroglu M., Mandel N.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.26, no.2, pp.121-123, 2003 (Journal Indexed in SCI)
- CXXXV. **Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature.**  
Aki H., BASLAR Z., UYGUN N., OZGUROGLU M., TUZUNER N.  
Urology, vol.60, pp.345, 2002 (Journal Indexed in SCI Expanded)
- CXXXVI. **Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.**  
Altiparmak M. R. , Bilici A., Kisacik B., Ozguroglu M.  
Medical oncology (Northwood, London, England), vol.19, no.2, pp.117-9, 2002 (Journal Indexed in SCI Expanded)
- CXXXVII. **Simultaneous presentation of hepatocellular carcinoma in identical twin brothers**  
Demir G., Belentepe S., Ozguroglu M., Celik A., Sayhan N., Tekin S., Mandel N., Buyukunal E., Serdengeçti S.  
MEDICAL ONCOLOGY, vol.19, no.2, pp.113-116, 2002 (Journal Indexed in SCI)
- CXXXVIII. **Metastatic cardiac myxoma**  
KAYNAK K., BESIRLI K., ARSLAN C., OZGUROGLU M., Oz B.  
ANNALS OF THORACIC SURGERY, vol.72, no.2, pp.623-625, 2001 (Journal Indexed in SCI)
- CXXXIX. **Serum erythropoietin level in anemic cancer patients**  
Ozguroglu M., Arun B., Demir G., Demirelli F. H. , Mandell N., Buyukunal E., Serdengeçti S., Berkarda B.  
MEDICAL ONCOLOGY, vol.17, no.1, pp.29-34, 2000 (Journal Indexed in SCI)
- CXL. **Vinorelbine plus infusional 5-fluorouracil in anthracycline and taxane refractory metastatic breast cancer: A pilot study**  
Ozguroglu M., Demir G., Demirelli F., Molinas Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.  
Journal of B.U.ON., vol.4, no.4, pp.367-372, 1999 (Journal Indexed in SCI Expanded)
- CXLI. **Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma**  
Ozguroglu M., Turna H., Demir G., Doventas A., Demirelli F. H. , Mandel N. K. , Buyukunal E., Serdengeçti S., Berkarda B.  
American Journal of Clinical Oncology: Cancer Clinical Trials, vol.22, no.6, pp.615-618, 1999 (Journal Indexed in SCI Expanded)
- CXLII. **Paraneoplastic hyperpigmentation secondary to lung cancer resolving after chemotherapy**  
Ozguroglu M., Tahan V., Ozguroglu E., Ozaras R., Demir G.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.5, pp.533-534, 1999 (Journal Indexed in SCI)
- CXLIII. **Anorectal melanoma metastatic to the breast**  
Ozguroglu M., Ozaras R., Tahan V., Demirkesen C., Demir G., Dogusoy G., Buyukunal E., Serdengeçti S., Berkarda B.  
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.29, no.2, pp.197-199, 1999 (Journal Indexed in SCI)
- CXLIV. **Chemoimmunotherapy protocol for advanced gastric cancer**  
Demir G., Ozguroglu M., Molinas-Mandel N., Relli F., Buyukunal E., Serdengeçti S., Berkarda B.  
EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (Journal Indexed in SCI)
- CXLV. **Serum erythropoietin level in anemic cancer patients**  
Ozguroglu M., Demir G., Demirelli F., Molinas-Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.  
EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (Journal Indexed in SCI)
- CXLVI. **Role of mammographic screening in ovarian cancer**  
Ozguroglu M., Esen G., Yildirim B., Demir G., Turna H., Demirelli F., Molinas-Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.  
EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (Journal Indexed in SCI)
- CXLVII. **Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma**  
Ozguroglu M., Demir G.  
CANCER, vol.86, no.3, pp.547-549, 1999 (Journal Indexed in SCI)
- CXLVIII. **Bilateral inflammatory breast metastases of epithelial ovarian cancer**  
Ozguroglu M., Ersavasti G., Ilvan S., Hatemi G., Demir G., Demirelli F. H.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.4, pp.408-410, 1999 (Journal Indexed in SCI)

- CXLIX. **Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)**  
Demir G., Ozguroglu M., Sayhan N., Molinas-Mandel N., Demirelli F. H. , Buyukunal E., Tuzuner N., Serdengecti S., Berkarda B.  
ANTICANCER RESEARCH, vol.19, pp.3517-3520, 1999 (Journal Indexed in SCI)
- CL. **Serum cardioliipin antibodies in cancer patients with thromboembolic events**  
Ozduroglu M., Arun B., Erzin Y., Demir G., Demirelli F., Mandel N., Buyukunal E., Serdengecti S., Berkarda B.  
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.5, no.3, pp.181-184, 1999 (Journal Indexed in SCI)
- CLI. **Primary splenic tuberculosis in a patient with nasal angiocentric lymphoma - Mimicking metastatic tumor on abdominal CT**  
Ozguroglu M., Celik A. F. , Demir G., Aki H., Demirelli F. H. , Mandel N. K. , Buyukunal E., Serdengecti S., Berkarda B.  
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.29, no.1, pp.96-98, 1999 (Journal Indexed in SCI)
- CLII. **Microangiopathic hemolytic anemia as an early predictor of recurrence in gastric cancer**  
Ozguroglu M., Demirelli F. H. , Mandel N. K.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.2, pp.214, 1999 (Journal Indexed in SCI)
- CLIII. **Anaphylaxis from intraperitoneal infusion of cisplatin - A case report**  
Ozguroglu M., Demir G., Demirelli F. H. , Mandel N. K.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.2, pp.172-173, 1999 (Journal Indexed in SCI)
- CLIV. **Unusual manifestations of B-cell disorders - Case 1: Multiple myeloma with predominant phalangeal involvement**  
Ozguroglu M., Aki H., Demir G., Demirelli F. H. , Mandel N. K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.17, no.3, pp.1083-1084, 1999 (Journal Indexed in SCI)
- CLV. **Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma**  
Özgüroglu M., Ersavasti G. E. , Demir G., Aki H., Demirelli F., Kanberoglu K., Mandel N., Büyükünäl E., Serdengecti S., Berkarda B.  
Pathology and Oncology Research, vol.5, no.2, pp.123-128, 1999 (Journal Indexed in SCI Expanded)
- CLVI. **Anaplastic large cell lymphoma of the duodenum fistulized to the colon: Leukocyte common antigen negativity leading to misdiagnosis as carcinoma**  
Ozguroglu M., Demir G., Dogysoy G., Korman U., Demirelli F., Mandel N., Buyukunal E., Serdengecti S., Berkarda B.  
Journal of B.U.ON., vol.4, no.2, pp.215-217, 1999 (Journal Indexed in SCI Expanded)
- CLVII. **Self expanding metal stents for palliation of dysphagia due to esophageal malignancies**  
Dobrucali A., Ozguroglu M., Demir G., Karahasanoglu T., Uzunismail H., Cebeci H., Oktay E., Dinc I.  
Turkish Journal of Gastroenterology, vol.10, no.1, pp.18-23, 1999 (Journal Indexed in SCI Expanded)
- CLVIII. **A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma**  
Icli F., Celik I., Aykan F., Uner A., Demirkazik A., Ozet A., Ozguroglu M., Tas F., Akbulut H., Firat D.  
CANCER, vol.83, no.12, pp.2475-2480, 1998 (Journal Indexed in SCI)
- CLIX. **Immune effects of low-dose subcutaneous interleukin-2 in patients with metastatic malignant melanoma**  
Demir G., Demirelli F., Ozguroglu M., Molinas-Mandel N., Buyukunal E., Tuzuner N., Serdengecti S., Berkarda B.  
INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, vol.14, no.3, pp.163-168, 1998 (Journal Indexed in SCI)
- CLX. **High dose epirubicin and cisplatin induction chemotherapy sequentially followed by ifosfamide and etoposide chemotherapy in extensive stage small cell lung cancer (ES-SCLC)**  
Demirkazik A., Onat H., Saip P., Ozguroglu M., Kars A., Cay F., Demir G., Uner A., Arpacı F., Aktan G.  
ANNALS OF ONCOLOGY, vol.9, pp.105, 1998 (Journal Indexed in SCI)
- CLXI. **Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma**  
Ozguroglu E., Buyulbabani N., Ozguroglu M., Baykal C.

- BRITISH JOURNAL OF DERMATOLOGY, vol.137, no.3, pp.422-425, 1997 (Journal Indexed in SCI)
- CLXII. **Magnetic resonance imaging of bone marrow versus biopsy in malignant lymphoma**  
Ozguroglu M., Ersavasti G., Demir G., Demirelli F., Tuzuner N., Kanberoglu K., Mandel N., Buyukunal E., Serdengeçti S.  
EUROPEAN JOURNAL OF CANCER, vol.33, pp.1220, 1997 (Journal Indexed in SCI)
- CLXIII. **NORADRENERGIC AND SEROTONINERGIC DEPRESSION**  
YAZICI O., ARICIOGLU F., GURVIT G., UCOK A., TASTABAN Y., CANBERK O., OZGUROGLU M., DURAT T., SAHIN D.  
JOURNAL OF AFFECTIVE DISORDERS, vol.27, no.2, pp.123-129, 1993 (Journal Indexed in SCI)
- CLXIV. **Spontaneous improvement of tardive dystonia during mania**  
Yazici O., Kantemir E., Tastaban Y., Ucok A., Ozguroglu M.  
British Journal of Psychiatry, vol.158, pp.847-850, 1991 (Journal Indexed in SSCI)

## Articles Published in Other Journals

- I. **Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.**  
Goldman J., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M., Özgüroğlu M., Ji J., et al.  
The Lancet. Oncology, 2020 (Journal Indexed in ESCI)
- II. **CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab +/- Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab +/- Tremelimumab**  
Reinmuth N., Paz-Ares L., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J., Ozguroglu M., Li H. J., Voitko O., et al.  
PNEUMOLOGIE, vol.74, 2020 (Journal Indexed in ESCI)
- III. **Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry**  
Akaza H., Procopio G., Pripatnanont C., Facchini G., Fava S., Wheatley D., Leung K. C., Butt M., Silva A., Castillo L., et al.  
JOURNAL OF GLOBAL ONCOLOGY, vol.4, 2018 (Journal Indexed in ESCI)
- IV. **Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.**  
Tural D., Serdengeçti S., Demirelli F. H., Öztürk T., İlvan Ş., Turna H., Ozguroglu M., Buyukunal E.  
British journal of cancer, vol.110, no.8, pp.1968-1976, 2014 (Refereed Journals of Other Institutions)
- V. **UNUSUAL PRESENTATION OF CERVICAL CARCINOMA METASTASIS TO THE BREAST: A CASE REPORT AND REVIEW OF THE LITERATURE**  
Yetmen O., Oksuz D. C., Demirkiran F., Ozguroglu M., Calay Z., Atkovar G., Sahinler I.  
JOURNAL OF BREAST HEALTH, vol.8, no.2, pp.92-96, 2012 (Journal Indexed in ESCI)
- VI. **Serviks kanserinin memeye sıra dışı metastazi: Olgu sunumu ve literatür değerlendirilmesi.**  
Yetmen Ö., ÇOLPAN ÖKSÜZ D., DEMİRKİRAN F., ÖZGÜROĞLU M., CALAY Z. Z., ATKOVAR G., ŞAHİNLER İ.  
Meme Sağlığı Dergisi, no.8, pp.92-96, 2012 (Other Refereed National Journals)
- VII. **Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease.**  
SELÇUKBİRİCİK F., TURAL D., ELICIN O., BERK S., Özgüroğlu M., BESE N., FERHANOĞLU B.  
ISRN oncology, vol.2012, pp.951816, 2012 (Refereed Journals of Other Institutions)
- VIII. **Mide karsinomlarında postoperatif kemoradyoterapi tedavi sonuçları: Cerrahpaşa deneyimi**  
ÇOLPAN ÖKSÜZ D., Eren M. F., BEŞE F. N., BÜYÜKÜNAL E., ÖZGÜROĞLU M., Mandel N. M., TURNA Z. H., DEMİRELLİ F. H., SERDENGEÇTİ A. S., ATKOVAR G., et al.  
TÜRK ONKOLOJİ DERGİSİ, no.25, pp.1-10, 2010 (Other Refereed National Journals)

- IX. The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpasa experience**  
Oksuz D. C. , Eren M. F. , Bese N. S. , Buyukunal E., Ozguroglu M., Mandel N. M. , TURNA Z. H. , Demirelli F., Serdengeçti S., Atkovar G., et al.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.25, no.1, pp.1-10, 2010 (Journal Indexed in ESCI)
- X. Skeletal muscle: An unusual site of distant metastasis in gastric carcinoma**  
Beşe N. Ş. , Özgüroğlu M., Dervişoğlu S., Kanberoğlu K., Öber A.  
Radiation Medicine - Medical Imaging and Radiation Oncology, vol.24, no.2, pp.150-153, 2006 (Refereed Journals of Other Institutions)
- XI. Pentoxifylline in the Treatment of Radiation-related Pelvic Insufficiency Fractures of Bone**  
Beşe N. Ş. , Özgüroğlu M., Kamberoğlu K., Karahasanoglu T., Öber A.  
Radiation Medicine - Medical Imaging and Radiation Oncology, vol.21, no.5, pp.223-227, 2003 (Refereed Journals of Other Institutions)
- XII. Uveal malign melanomlu olguların retrospektif değerlendirilmesi-tedavi yaklaşımı ve sonuçları**  
ÖZGÜROĞLU M., Pazarlı H., ÖZARAS R., Demir G., Tahan V., Demirelli F. H. , Mandel N. M. , Büyükinal E., Serdengeçti S., Berkarda B.  
AVICENA, vol.1, pp.30-32, 1999 (Other Refereed National Journals)
- XIII. Kadınlarda primeri bilinmeyen aksiller karsinom metastazına yaklaşım: iki olgu bildirim**  
ÖZGÜROĞLU M., Tahan V., ÖZARAS R., Demir G., Çerçel A., Demirelli F. H. , Mandel N. M. , Büyükinal E., Serdengeçti S., Berkarda B., et al.  
Meme Hastalıkları Dergisi, vol.5, pp.172-175, 1998 (Other Refereed National Journals)
- XIV. The effects of tamoxifen on endometrium of patients with breast cancer Meme kanserli hastalarda tamoksifen tedavisinin yapmış olduğu endometriyum değişiklikleri**  
Kosebay D., Arvas M., Bese T., Demirkiran F., Mandel N., Ozguroglu M., Bese N., Ober A., Okkan S.  
Jinekoloji ve Obstetrik Dergisi, vol.10, no.2, pp.68-73, 1996 (Refereed Journals of Other Institutions)

## Refereed Congress / Symposium Publications in Proceedings

- I. LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)**  
Lu S., Casarini I., Kato T., Cobo Dols M., Ozguroglu M., Zeng L., van der Gronde T., Saggese M., Ramalingam S.  
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 November 2020, vol.31
- II. Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials**  
Ozguroglu M., Shitara K., Lee K., Fuchs C. S. , Chung H. C. , Di Bartolomeo M., Chao J., Wainberg Z. A. , Caglevic C., Kudaba I., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- III. Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound**  
Roubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , Procopio G., Feyerabend S., Joung J. Y. , Gravis G., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- IV. Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations**  
de Bono J. S. , Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K. N. , Sartor O., Agarwal N., Olmos D., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- V. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1)  $\geq$  50%**



Sezer A, KILIÇKAP S, GÜMÜŞ M, Bondarenko I, Ozguroglu M, Gogishvili M, TÜRK H. M. , Cicin I, Bentsion D, Gladkov O, et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

- VI. **Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361**  
Alva A, Csoszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng S. Y. , Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- VII. **Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study**  
Baciarello G, Ozguroglu M, Mundle S. D. , Leitz G, Richarz U, Hu P, Chi K. N. , Fizazi G.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- VIII. **Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial**  
Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste J. F. , Spigel D. R. , Garassino M. C. , Reck M, Senan S, et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- IX. **Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN**  
Goldman J. W. , Garassino M. C. , Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair M. J. , Ozguroglu M, Ji J. H. , et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- X. **KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma**  
Yoon H, Fuchs C, Ozguroglu M, Bang Y, Di Bartolomeo M, Mandala M, Ryu M, Fornaro L, Olesinski T, Caglevic C, et al.  
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 July 2020, vol.31
- XI. **APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES**  
Chowdhury S, Bjartell A, Agarwal N, Chung B. H. , Given R. W. , Pereira de Santana Gomes A. J. , Merseburger A. S. , Ozguroglu M, Juarez Soto A, Uemura H, et al.  
Annual Meeting of the American-Urological-Association (AUA), Washington, Kiribati, 15 - 18 May 2020, vol.203
- XII. **Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy**  
Chao J, Fuchs C. S. , Shitara K, Taberero J, Muro K, Van Cutsem E, Bang Y, De Vita F, Landers G. A. , Yen C, et al.  
Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica, 23 - 25 January 2020, vol.38
- XIII. **Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)**  
Agarwal N, Chowdhury S, Bjartell A, Chung B. H. , Gomes A. J. P. d. S. , Given R. W. , Soto A. J. , Merseburger A. S. , Ozguroglu M, Uemura H, et al.  
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38
- XIV. **PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)**  
Huddart R. A. , Siefker-Radtke A. O. , Balar A. V. , Bilen M. A. , Powles T, Bamias A, Castellano D, Khalil M. F. , Van der Heijden M. S. , Koshkin V. S. , et al.  
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38
- XV. **Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L)**

**chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)**

Moehler M. H. , Dvorkin M., Ozguroglu M., Ryu M., Muntean A. S. , Lonardi S., Nechaeva M., Bragagnoli A. S. C. , Coskun H. S. , Gracian A. C. , et al.

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica, 23 - 25 January 2020, vol.38

- XVI. **Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease**  
Ozguroglu M., Chowdhury S., Bjartell A., Uemura H., Chung B. H. , Agarwal N., Merseburger A. S. , Soto A. J. , Lopez-Gitlitz A., Bhaumik A., et al.  
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38
- XVII. **PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations**  
De Bono J. S. , Fizazi K., Saad F., Shore N. D. , Roubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Procopio G., et al.  
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38
- XVIII. **Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience**  
Samanci N., Oruc K., Bedir S., Celik E., Degerli E., Derin S., Demirelli F. H. , Ozguroglu M.  
Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30
- XIX. **First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN**  
Ozguroglu M., Goldman J. W. , Reinmuth N., Chen Y., Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J. H. , Hochmair M. J. , et al.  
Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30, pp.66
- XX. **Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study**  
Herbst R. S. , de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., Geater S., et al.  
Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30, pp.62-63
- XXI. **Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia**  
Nishio M., Ji J. H. , Hotta K., Chiu C., Lee J., Azuma K., Kim S., Wu S., Dvorkin M., Trukhin D., et al.  
European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019, vol.30
- XXII. **Three-year overall survival update from the PACIFIC trial**  
Wu Y., Gray J. E. , Villegas A., Daniel D. B. , Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , et al.  
European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019, vol.30
- XXIII. **Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study**  
Chung B. H. , McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J. , Ozguroglu M., Juarez Soto A., Merseburger A. S. , Uemura H., Ye D., et al.  
European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019, vol.30

- XXIV. **IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC**  
Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z. G. , Geater S., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.915
- XXV. **Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)**  
Barlesi F., Ozguroglu M., Vansteenkiste J. F. , Spigel D., Yang J. C. , Bajars M., Ruisi M., Manitz J., Park K.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- XXVI. **Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)**  
Van Cutsem E., Amonkar M., Fuchs C. S. , Alsina M., Ozguroglu M., Bang Y., Chung H. C. , Muro K., Goekkurt E., Benson A., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.304
- XXVII. **IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)**  
Grande E., Galsky M., Arranz Arijia J. A. , De Santis M., Davis I. D. , De Giorgi U. F. F. , Mencinger M., Kikuchi E., Garcia del Muro X., Gumus M., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.888-889
- XXVIII. **PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN**  
Paz-Ares L., Goldman J. W. , Garassino M. C. , Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J. H. , Hochmair M. J. , Voitko O., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.928-929
- XXIX. **Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study**  
de Bono J. S. , Fizazi K., Saad F., Shore N., Sandhu S. K. , Mehra N., Kolinsky M., Roubaud G., Ozguroglu M., Matsubara N., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.328-329
- XXX. **Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)**  
Vansteenkiste J. F. , Naidoo J., Faivre-Finn C., Ozguroglu M., Villegas A., Daniel D., Murakami S., Hui R., Lee K. H. , Cho B. C. , et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.592-593
- XXXI. **Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)**  
Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Gomes A. J. P. D. S. , Chung B. H. , Ozguroglu M., Juarez Soto A., Merseburger A., Uemura H., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30

- XXXII. **A challenging task - Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience**  
Pauli C., Bochtler T., Mileschkin L., Baciarello G., Losa F., Ross J., Pentheroudakis G., Zarkavelis G., YALÇIN Ş., Ozguroglu M., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- XXXIII. **Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged  $\geq$  65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.**  
Shitara K., Doi T., Hosaka H., Thuss-Patience P. C., Santoro A., Jimenez-Fonseca P., Longo F., Ozyilkan O., Cicin I., Park D., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XXXIV. **Three-year overall survival update from the PACIFIC trial.**  
Gray J. E., Villegas A. E., Daniel D. B., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H., Cho B. C., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XXXV. **First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.**  
Planchard D., Cho B. C., Gray J. E., Paz-Ares L. G., Ozguroglu M., Villegas A. E., Daniel D. B., Vicente D., Murakami S., Hui R., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XXXVI. **First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).**  
Chi K. N., Agarwal N., Bjartell A., Chung B. H., Gomes A. J. P. d. S., Given R. W., Soto A. J., Merseburger A. S., Ozguroglu M., Uemura H., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XXXVII. **Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)**  
Woo H., Fizaz K., Sulur G., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B., Ozguroglu M., Ye D., et al.  
Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Brisbane, Australia, 13 - 16 April 2019, vol.123, pp.27-28
- XXXVIII. **Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).**  
Fizazi K., Namphuong Tran N. T., Fein L. E., Matsubara N., Antolin A. R., Ozguroglu M., Ye D., Feyerabend S., Protheroe A., Sulur G., et al.  
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Costa Rica, 28 February - 02 March 2019, vol.37
- XXXIX. **PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC**  
Raben D., Faivre-Finn C., Spigel D., Daniel D., Villegas A., Vincente D., Hui R., Carpeno J. d. C., Murakami S., Paz-Ares L., et al.  
60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Northern Mariana Islands, 21 - 24 October 2018, vol.102, pp.1607-1608
- XL. **Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer**

Lin C., Taylor M., Boni V., Brunsvig P. F., Geater S. L., Salvagni S., Garrido Lopez P., Ozguroglu M., Sriuranpong V., Ponce Aix S., et al.

43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.413

- XLII. **LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)**  
Matsubara N., Chi K. N., Ozguroglu M., Rodriguez Antolin A., Feyerabend S., Fein L., Alekseev B. Y., Suler G., Protheroe A., Li S., et al.  
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29
- XLIII. **Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer**  
Kato K., Shah M. A., Enzinger P. C., Bennouna J., Shen L., Adenis A., Sun J., Cho B. C., Ozguroglu M., Kojima T., et al.  
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29
- XLIII. **Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC**  
Faivre-Finn C., Spigel D. R., Senan S., Langer C. J., Raben D., Perez B., Ozguroglu M., Daniel D., Villegas A., Vicente D., et al.  
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.488
- XLIV. **KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer**  
Shitara K., Ozguroglu M., Bang Y. J., Di Bartolomeo M., Mandala M., Ryu M. H., Fornaro L., Olesinski T., Caglevic C., Chung H., et al.  
ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 20 - 23 June 2018, vol.29
- XLV. **A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress**  
Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., Sun J., Cho B., Ozguroglu M., Kojima K., et al.  
ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 20 - 23 June 2018, vol.29
- XLVI. **An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting**  
Cicin I., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Slim B. A., Uslu R., Errihani H., Alsalef K., Belbaraka R., et al.  
11th European Breast Cancer Conference (EBCC), Barcelona, Spain, 21 - 23 March 2018, vol.92
- XLVII. **JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).**  
Moehler M. H., Ryu M., Lee K., Coskun H. S., Wong R., Ozguroglu M., Chung H., Poltoratsky A., Tsuji A., Yen C., et al.  
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36
- XLVIII. **PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer**  
Antonia S. J., Villegas A., Daniel D., Baz D. V., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K. H., de Wit M., et al.  
59th Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO), California, United States Of America, 24 - 27 September 2017, vol.99, pp.1314-1315
- XLIX. **PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC**  
Paz-Ares L., Villegas A., Daniel D., Baz D. V., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K. H., de Wit M., et al.  
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- L. **JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+non-small-cell lung cancer (NSCLC)**  
Reck M., Yang C., Postmus P. E., Barlesi F., Font E. F., Thomas M., Kim T. M., Dols M. C., Skuladottir H., Park K., et al.

- 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- L.I. **Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4**  
Bachelot T, Royce M, Villanueva C, Melo Cruz F, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce C. H. , Ridolfi A., et al.  
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- L.II. **LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer**  
Fizazi K, Tran N, Fein L. E. , Matsubara N, Antolin A. R. , Alekseev B. Y. , Ozguroglu M, Ye D, Feyerabend S, Protheroe A., et al.  
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- L.III. **Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.**  
Cardoso F, Villanueva C, Royce M, Cruz F, Debled M, Hegg R, Toyama T, Falkson C. I. , Jeong J, Srimuninnimit V, et al.  
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- L.IV. **Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial**  
Villanueva C, Tsugawa K, Toyama T, Noh W, Jeong J, Cardoso F, Sriuranpong V, Srimuninnimit V, Ozguroglu M, Kendall S., et al.  
San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 6 - 10 December 2016, vol.77
- L.V. **TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)**  
Chi K. N. , Chowdhury S, Radziszewski P, Le Bret T, Ozguroglu M, Sternberg C, Sims R. B. , Yu M, Naini V, Darif M, et al.  
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- L.VI. **BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)**  
Royce M, Villanueva C, Ozguroglu M, Bachelot T, Azevedo S, Melo Cruz F, Hegg R, Debled M, Gradishar W. J. , Manlius C., et al.  
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- L.VII. **Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.**  
Reck M, DeGreen H. P. , Rose A. L. , Pavlakis N, Derjcke S. M. , Radic J, Jeppesen N, Thomas M, Losonczy G, Kalinka-Warzocho E., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- L.VIII. **Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3**  
Isaacs C, O'Regan R, Xu B, Masuda N, Arena F, Yap Y, Papal Z, Lang I, Armstrong A, Lerzo G., et al.  
38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 12 December 2015, vol.76

- LIX. **Treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis**  
Akaza H., Procopio G., Pripatnanont C., Facchini G., Fava S., Wheatley D., Leung K. C., Butt M., Silva A., Castillo L., et al.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- LX. **Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting**  
Oudard S., Angelergues A., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., Ozguroglu M., Flechon A., Guillot A., Le Moulec S., et al.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- LXI. **Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel**  
Angelergues A., Bellmunt J., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., Ozguroglu M., Flechon A., Guillot A., Le Moulec S., et al.  
European Cancer Congress / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 25 - 29 September 2015, vol.51
- LXII. **Prognostic value of baseline Neutrophil to Lymphocyte Ratio (NLR) in metastatic Urothelial Carcinomas (mUC) patients (pts) treated with first-line chemotherapy (CT): A large retrospective multicenter study**  
Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., Caty A., Dujardin C., Auclin E., Tartour E., et al.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- LXIII. **Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multicenter study from Turkey**  
Celik I., Mandel N. M., Gokmen E., Unal O. U., Sevinc A., Coskun H. S., Buyukberber S., Abali H., Ozguroglu M., Utkan G., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- LXIV. **Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).**  
Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al.  
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32
- LXV. **ER/PR/HER2 receptor discordance between primary tumors and corresponding axillary metastases in curatively resected node positive breast cancer patients**  
Ozturk M., Turna H., Aydin O., Tural D., Demirelli F., Ozguroglu M., Buyukunal E., Ilvan S., Serdengeci S.  
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49
- LXVI. **Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies**  
Tural D., Demirelli F., Serdengeci S., ÖZTÜRK T., Ilvan S., Turna H., Ozguroglu M., Buyukunal E.  
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49
- LXVII. **Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).**  
O'Regan R., Ozguroglu M., Andre F., Toi M., Jerusalem G. H. M., Wilks S., Isaacs C., Xu B., Masuda N., Arena F. P., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LXVIII. **Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter**

Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

**LXXIX. IMPACT OF CABAZITAXEL (CBZ) plus PREDNISONE (P; CBZP) ON OVERALL SURVIVAL (OS) AT 2 YRS AND IN PATIENTS (PTS) WITH AGGRESSIVE DISEASE: POST-HOC ANALYSES OF TROPIC TRIAL**

Oudard S., de Bono J. S., Ozguroglu M., Hansen S., Machiels J., Kocak I., Gravis G., Bodrogi I., Shen L., Sartor A. O.  
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.307-308

**LXX. Thromboembolic complications in cancer patients.**

Yenidunya G., Turna H., Ozturk M. A., Tural D., Selcukbiricik F., Yildiz O., Ozguroglu M., Demirelli F., Buyukunal E., Serdengecti S.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

**LXXI. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.**

Bavbek S. E., Malik Z. I., Di Lorenzo G., Scholz H., van Oort I. M., Siobhan Ng S. N., Ozguroglu M., Gerritsen W. R., Mueller S., Marttila T., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

**LXXII. NOD POZİTİF MEME KANSERLERİNDE PRİMER TÜMÖR VE AKSİLLER METASTAZIN ER, PR VE HER2 EKSPRESYONU AÇISINDAN KARŞILAŞTIRILMASI**

ÖZTÜRK M. A., AYDIN Ö., İLVAN Ş., TURNA Z. H., TURAL D., YILDIZ Ö., ÖZGÜROĞLU M., BÜYÜKÜNAL E., SERDENGEÇTİ S.

4. TIBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 21 - 25 March 2012, pp.103

**LXXIII. Preoperative Chemoradiotherapy Improves Local Recurrence Free Survival in Locally Advanced Rectal Cancer**

Turhal D., Ozturk M. A., Yildiz O., Selcukbiricik F., Elicin O., Erguney S., Ozguroglu M.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47

**LXXIV. Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer**

Turna Z. S., Ozturk M. A., Tural D., Biricik F. S., Yildiz O., Ozguroglu M., Demirelli F., Mandel N. M., Buyukunal E., Serdengecti S.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47

**LXXV. KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?**

Selcukbiricik F., Yildiz O., Tural D., Ozturk M. A., Demir G., Ozguroglu M., Erdamar S., Buyukunal E., Mandel N. M., Serdengecti S.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47

**LXXVI. Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen - Interim Analysis Results From an Ongoing Compassionate-use Programme**

Heidenreich A., Scholz H. J., van Oort I., Bavbek S., Mueller S., Ozguroglu M., Albers P., Gschwend J., Ecstein-Fraisse E.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47

**LXXVII. INCREASING ROLE OF METASTASECTOMY IN METASTATIC BREAST CANCER PATIENTS: WHO BENEFITS MORE**

Selcukbiricik F., Ozguroglu M., Öztürk M. S., Turna H., Tural D., Yildiz O., Demirelli F., Serdengecti S.



- 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.111
- LXXVIII. **THE EFFECTS OF PATIENT AND TUMOR CHARACTERISTICS AND TREATMENT MODALITIES ON PROGNOSIS OF PATIENTS WITH UVEAL MELANOMA**  
Tural D., Ozguroglu M., Turna H., Selcukbiricik F., Ozturk M. A. , Sevinc M., Demirkesen C., Sarici A., Pazarli H., Serdengecti S.  
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.406
- LXXIX. **CABAZITAXEL PLUS PREDNISONE/PREDNISOLONE SIGNIFICANTLY INCREASES OVERALL SURVIVAL COMPARED TO MITOXANTRONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: FINAL RESULTS WITH UPDATED OVERALL SURVIVAL OF A MULTINATIONAL PHASE III TRIAL (TROPIC)**  
Oudard S. M. , De Bono J. S. , Ozguroglu M., Hansen S., Machiels J., Shen L., Gupta S., Sartor A. O.  
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.272
- LXXX. **Is there any future of prophylactic cranial irradiation in adenocarcinoma of the lung?**  
Ozguroglu M., Turna H., Sevinc M., Karaaslan S., Gursu U. R.  
15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Germany, 20 - 24 September 2009, vol.7, pp.534
- LXXXI. **The effects of prognostic factors on the first recurrence patterns of breast cancer**  
Turna H., Ozguroglu M., Demir G., Mandel N., Ilvan S., Calay Z., Buyukunal E., Serdengecti S.  
15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Germany, 20 - 24 September 2009, vol.7, pp.312
- LXXXII. **AWARENESS OF CANCER DIAGNOSIS IN TURKISH CANCER PATIENTS AND ATTITUDES OF PHYSICIANS AND NURSES TOWARDS DISCLOSURE OF THE DIAGNOSIS**  
Sayilir A., Ozguroglu M., Turna H.  
33rd European-Society-for-Medical-Oncology Congress, Stockholm, Sweden, 12 - 16 September 2008, vol.19, pp.263
- LXXXIII. **CHARACTERISTICS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS**  
Turna H., Ozguroglu M., Guersu R. U. , Karaaslan S., Yildiz O., Yanmaz M. T.  
33rd European-Society-for-Medical-Oncology Congress, Stockholm, Sweden, 12 - 16 September 2008, vol.19, pp.256-257
- LXXXIV. **MULTICENTER, PHASE II STUDY OF LAROTAXEL IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) PROGRESSING AFTER ANTHRACYCLINES, TAXANES AND CAPECITABINE**  
Ozguroglu M., Mansutti M., Kerr R., Awada A., Rha S. Y. , Im Y. H. , Perez Manga G., Germann N., Fumoleau P.  
33rd European-Society-for-Medical-Oncology Congress, Stockholm, Sweden, 12 - 16 September 2008, vol.19, pp.69
- LXXXV. **Trastuzumab beyond progression in metastatic breast cancer**  
Yanmaz M. T. , Ozguroglu M., Ozturk B., Uygun K., Basaran G., Turna H., Yildiz O., Baran A., Demir G., Buyukunal E.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.77
- LXXXVI. **Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty**  
Yildiz I., Mandel N. M. , Demir G., Ozguroglu M., Toptas T., Buyukunal E., Serdengecti S.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.164
- LXXXVII. **Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)**  
Ozguroglu M., Evrensel T., Er O., Turna H., Yanmaz T., Yildiz O., Mandel N., Serdengecti S.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.225
- LXXXVIII. **The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma**  
Bese N., Yildirim A., Ober A., Ozguroglu M., Mandel N., Demir G., Demirelli F., Serdengecti S., Buyukunal E.

23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Netherlands, 24 - 28 October 2004, vol.73

**LXXXIX. Gastric cancer in Turkey: A single center experience of 683 cases**

Demir G., Buyukunal E., Kizilkilic E., Ozguroglu M., Mandel N., Demirelli F., Serdengecti S.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

**XC. Is the incidence of anal canal cancers different in Moslem societies?**

Cabuk D., Yumuk P., Abacioglu U., Demir G., Dane F., Gumus M., Ozguroglu M., Ekenel M., Basaran G., Turhal N.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

**XCI. The acute phase proteins in cancer patients**

Bolayirli I., Ozguroglu M., Balci H., Orhanoglu T., Hacibekiroglu M.

56th Annual Meeting of the American-Association-for-Clinical-Chemistry, Los-Angeles, Chile, 25 - 29 July 2004, vol.50

**XCII. Significance of serum beta-2 microglobulin in epithelial ovarian cancer**

ÖZGÜROĞLU M., Tahan V., Demir G., ÖZARAS R., Demirelli F. H. , Mandel N. M. , Büyükinal E., Serdengeçti S., Berkarda B.

35th Annual Meeting , American Society of Clinical Oncology., Atlanta, United States Of America, 15 - 18 May 1999, vol.1, pp.382

**XCIII. Uveal Malign Melanomlu Olguların Retrospektif Değerlendirilmesi-tedavi Yaklaşımı ve Sonuçları**

ÖZGÜROĞLU M., Demir G., ÖZARAS R., Tahan V., Pazarlı H., Demirelli F. H. , Mandel N. M. , Büyükinal E., Serdengeçti S., Berkarda B.

XIII. Ulusal Kanser Kongresi, Antalya, Turkey, 27 April - 01 May 1999, vol.1, pp.310

**XCIV. Chemoimmunotherapy protocol in patients with advanced gastric cancer**

Demir G., Ozguroglu M., Belentepe S., Demirelli F., Mandel N., Buyukunal E., Serdengecti S., Berkarda B.

2nd Congress of the Balkan-Union-of-Oncology, İzmir, Turkey, 10 - 14 September 1998, pp.407-411

**XCIV. THE ROLE OF LOCAL RADIATION THERAPY IN NEOADJUVANT PROTOCOL OF OSTEOSARCOMA**

Uzel M., HIZ V. M. M. , AYDINGÖZ Ö., Okkan S., KOCA S. S. , Molinas N., ÖZGÜROĞLU M., DERVİŞOĞLU S., Girişken G., Kanberoglu K.

2ND OSTEOSARCOMA RESEARCH CONFERENCE ABSTRACT BOOK, Italy, 1 - 04 November 1996, pp.21

## Supported Projects

2012 - 2012	Meme kanserinde östrojen reseptörü, progesteron reseptörü ve Her 2 ekspresyonunun primer tümör ve metastazdaki durumunun belirlenmesi ve tedavi planı üzerine etkisi, Project Supported by Higher Education Institutions
-------------	--

## Memberships / Tasks in Scientific Organizations

2017 - Continues	FACULTY MEMBER of genitourinary cancers in ESMO, Member of Advisory Board
2013 - Continues	BOLERO 4 ÇALIŞMASINDA STEERING COMMITTE ÜYELİĞİ, Board Member
2012 - Continues	PROXIMA ÇALIŞMASINDA STEERING COMMITTEE ÜYELİĞİ, Board Member
2021 - 2021	ESMO 2021, Member of Science Committee

## Scientific Consultations

2020 - Continues	Scientific Consultancy, MSD
2020 - Continues	Scientific Consultancy, MSD
2018 - Continues	Scientific Consultancy, JANSSEN

2013 - Continues	Project Consultancy, MEME KANSERİ ÇALIŞMASI
2012 - Continues	Project Consultancy, PROSTAT KANSERİ ÇALIŞMASI
2020 - 2023	Scientific Consultancy, BAYER

## **Tasks In Event Organizations**

14 Eylül 2021	Özgüroğlu M., ESMO, Scientific Congress, Paris, France
---------------	--

## **Invited Congress and Symposium Activities**

2019	ESMO-IO, Invited Speaker, Geneve, Switzerland
------	---

## **Invited Talks**

November 2020	PROFOUND STUDY, Seminar, United States Of America
---------------	---

## **Awards**

October 2004	best poster in ESMO meeting -pain in cancer patients, ESMO
July 1999	1999 yılındaki SCI ve SCIE kapsamındaki dergilerde uluslararası yayın sıralamasında birincilik ödülü, istanbul üniversitesi